mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Study efficacy measures will include the expression of dystrophin protein and motor function.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Enabling wireless monitoring In ambulances and homes
Subscribe To Our Newsletter & Stay Updated
